Publications by authors named "S Mielke"
Article Synopsis
- Prophylaxis strategies for Graft versus Host Disease (GVHD) in allogeneic hematopoietic cell transplantation (allo-HCT) often include a calcineurin inhibitor (CNI) combined with either methotrexate (MTX) or mycophenolate mofetil (MMF).
- A study analyzing data from 13,699 patients revealed that MTX-based prophylaxis was linked to lower overall mortality and non-relapse mortality compared to MMF, while showing no significant impact on relapse rates or relapse-free survival.
- Overall, MTX in combination with CNI was associated with better survival outcomes and a lower risk of severe acute GVHD compared to MMF.
In patients diagnosed with B-acute lymphoblastic leukemia (B-ALL) or B-non-Hodgkin's lymphoma (B-NHL) relapsing after allogeneic stem cell transplantation (allo-HCT), it is a standard practice to perform anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. When collected from the patient after allo-HCT, the produced CAR-T cells are likely to be donor T-cell-derived, creating unknown safety risks due to their potential allo-reactivity. We therefore performed an EBMT registry-based study on the incidence of graft-versus-host disease (GvHD) in this setting.
View Article and Find Full Text PDFAutologous hematopoietic cell transplants (auto-HCTs) remain the standard of care for transplant-eligible MM patients. The general practice has been to undergo upfront apheresis following induction to collect sufficient number of CD34+ cells to facilitate two auto-HCTs. However, 5-30% of MM patients do not initially mobilise a sufficient number of hematopoietic stem cells and are classified as poor mobilizers (PM).
View Article and Find Full Text PDFArticle Synopsis
- Immunocompromised patients have shown weak responses to initial SARS-CoV-2 mRNA vaccinations, prompting recommendations for extra booster doses; however, real-world data on these recommendations is limited.
- A two-year follow-up of the COVAXID clinical trial involved 364 participants, focusing on their immune responses and the effects of their vaccination schedule and underlying health conditions.
- The study found that while some patients who initially had poor responses improved after additional doses, their immune response remained affected by their immunosuppressive status, emphasizing the need for ongoing vaccination efforts in these populations.